AXL and chronic myelogenous leukemia, BCR-ABL1 positive: The oncogenic properties of AXL were initially described in patients with chronic myelogenous and lymphoblastic leukemia (CML), but overexpression of AXL have also been detected in many solid tumors and associated with poor prognosis [23].